Community HealthPathways
Hunter New England

COVID-19 Vaccination Referrals and Advice

Community HealthPathways Hunter New England

PRIMARY HEALTH NETWORK

patient info Central Coast & Hunter New England

NSW Government Health Hunter New England Local Health District

eReferral SeNT

Username: hnehealth
Password: p1thw1ys



Health Alert

All HNE healthcare settings within lockdown LGAs are on red alert.

COVID-19 information:

- COVID-19 Vaccination
- COVID-19 Testing and Advice
- COVID-19 pages

NSW Health – Latest COVID-19 Case Locations and Alerts

NSW Government – Travel to and from NSW

Hunter New England

COVID-19 Vaccination

In This Section

COVID-19 Vaccination Information

COVID-19 Vaccination Procedure

COVID-19 Vaccine-induced Thrombosis with Thrombocytopenia Syndrome (TTS)

COVID-19 Vaccination Referrals and Advice

Hunter New England

COVID-19 Vaccination Referrals and Advice

Vaccination referrals

Vaccination advice

Adverse event reporting

The patient noted above has a history of the following medical condition/s and it is recommended they receive the Pfizer (COMIRNATY™) COVID-19 vaccine according to current ATAGI advice.

- ☐ Cerebral venous sinus thrombosis (CVST)
- ☐ Heparin-induced thrombocytopenia (HIT)
- ☐ Idiopathic splanchnic (mesenteric, portal, splenic) vein thrombosis
- ☐ Antiphospholipid syndrome (APLS) with thrombosis and/or miscarriage
- ☐ Capillary leak syndrome
- ☐ Anaphylaxis, thrombosis with thrombocytopenia syndrome (TTS) or other serious adverse event attributed to the first dose of the AstraZeneca COVID-19 vaccine
- ☐ History of anaphylaxis to a component of the AstraZeneca COVID-19 vaccine

Hunter New England

COVID-19 Vaccination Referrals and Advice

Vaccination referrals

1. To refer patients for vaccination, use the Vaccine Eligibility Checker to confirm eligibility and identify the closest vaccination location.
2. Refer patients aged > 60 years with indications for Pfizer vaccine to an HNE LHD vaccination hub by emailing HNELHD-COVIDClinicBookingChange@health.nsw.gov.au with the subject header "Community GP – Patient booking referral", and either:
   - Include indication for vaccination with Pfizer (Comirnaty) in preference to AstraZeneca (ChAdOx1-S)

     or

   - Attach a completed Recommendation to Receive the Pfizer (Comirnaty) COVID-19 Vaccine Form
3. Consider vaccination options for:
   - residential aged care facility (RACF) staff

Also see AusVaxSafety COVID-19 vaccine data for reports received by routine active surveillance.

Significant (rare) syndromes reported to date internationally include

- disorders of clotting and haemostasis
- anaphylaxis
- Bell's palsy
- persistent lymphadenopathy
- other new onset neurological disorders.

Note: Many conditions can arise during normal life, whether or not a vaccine is administered. It remains important to report any new or unexpected events so that safety can be appropriately monitored.

Table 2: Frequency of selected adverse events following COVID-19 AstraZeneca vaccine (ChAdOx1-S)

Non-serious adverse events (generally milder and less frequent in older adults ≥65y)

Adverse reactions	Frequency COVID-19 Vaccine (AstraZeneca)	Frequency Control	Notification required
Injection site tenderness	63.7%	39.5%	
Fever	7.9%	1.2%	
Fatigue	53.1%	38.2%	No
Malaise	44.2%	20.2%	Do not require mandatory notification unless concerned,
Headache	52.6%	39.0%	more serious, persistent or not resolving.
Chills	31.9%	8.3%	
Muscle pain	44.0%	21.6%	
Joint pain	26.4%	12.4%	
Nausea	21.9%	13.1%	

Serious adverse events

Adverse reactions	Frequency	Notification required
Neurological demyelinating events	Very rare	Tes Requires mandatory notification.
Anaphylaxis or other hypersensitivity	Very rare (around 1/1,000,000)	These and any other rare, unusual or unexpected events leading to hospitalisation, disability or death must be reported urgently.

Frequency of selected adverse events following BNT162b2 (Pfizer-BioNTech) (30µg/dose) immunisation

Non-serious adverse events (frequency reported within 7 days following each dose in phase II/III trial)

Adverse reactions	Frequency Dose 1 (16-55y)	Frequency Dose 2 (16-55y)	Frequency Dose 1 (>55y)	Frequency Dose 2 (>55y)	Notification required
Injection site pain	83.1%	77.8%	71.1%	66.1%	No Does not require mandatory notification unless concerned, more serious, persistent or not resolving.
Fever	3.7%	15.8%	1.4%	10.9%	
Fatigue	47.4%	59.4%	22.6%	50.5%	
Headache	41.9%	51.7%	25.2%	39%	
Chills	14%	35.1%	6.3%	22.7%	
Muscle pain	21.3%	37.3%	13.9%	28.7%	
Joint pain	11%	21.9%	8.6%	18.9%	
Required paracetamol	27.8%	45%	19.9%	37.7%	

Serious adverse events

Adverse reactions	Frequency	Notification required
Severe persistent lymphadenopathy or injection site pruritis lasting longer than one week, pain not at the injection site (excluding headache or muscle/joint pain)	Uncommon (≥1/1,000 to <1/100))	Yes These and any other rare, unusual or unexpected events leading to hospitalisation, disability or death must be reported urgently
Acute peripheral facial paralysis (Bell's palsy)	Rare (≥1/10,000 to <1/1,000))	
Anaphylaxis or other hypersensitivity	Rare (around 1/200,000)	

Source: Australian Product Information - COMIRNATY™(BNT162b2 [mRNA]) COVID-19 Vaccine.